Drug intelligence / Profile preview

pra-027

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PRA-027 is a progesterone receptor (PR) modulator developed as a potential therapeutic agent for conditions such as uterine leiomyoma (fibroids). It was initially developed by Pfizer, following acquisition of Wyeth. The drug has undergone clinical trials to assess its safety, tolerability, pharmacokinetics (how the drug is absorbed, metabolized, and excreted), and pharmacodynamics (its biological activity in the body) in both cycling and postmenopausal women[2][1][4]. The mechanism of action involves modulation of the progesterone receptor[2].

Targets

PR (Progesterone receptor)

Beyond the preview

Go deeper on pra-027.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pra-027.

Explore the full profile